<DOC>
	<DOCNO>NCT00645632</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , ifosfamide , methotrexate , cisplatin , doxorubicin , work different way stop growth tumor cell , either kill cell stop divide . Giving chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Giving surgery may kill tumor cell remain surgery . PURPOSE : This clinical trial study well combination chemotherapy work treat patient undergo surgery newly diagnose high-grade osteosarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients Undergoing Surgery Newly Diagnosed High-Grade Osteosarcoma</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate efficacy new induction regimen comprise ifosfamide combination high-dose methotrexate , cisplatin , doxorubicin hydrochloride , term clinical response pathological response tumor , patient newly diagnose high-grade osteosarcoma . - To determine overall survival disease-free survival patient . - To evaluate toxicity regimen . - To correlate MRI image primary tumor histopathologic grade treatment regimen . OUTLINE : This multicenter study . - Neoadjuvant chemotherapy ( week 1-15 ) : Patients receive ifosfamide IV 1 hour day 1-5 36-40 ; doxorubicin hydrochloride IV 18 hour day 1-3 36-38 IV 72 hour day 71-73 ; high-dose methotrexate IV 4 hour day 22 , 29 , 57 , 64 , 92 , 99 ; cisplatin IV 4 hour day 71 . - Surgery ( week 16 ) : Patients undergo resection tumor day 106 . Patients find unresectable disease treat alternative protocol unless clear clinical pathologic response treatment . - Adjuvant chemotherapy ( week 18-43 ) : Beginning 2 week surgery , patient receive ifosfamide IV 1 hour day 120-124 , 155-159 , 225-229 , 260-264 ; doxorubicin hydrochloride IV 18 hour day 120-122 155-157 IV 72 hour day 190-192 ; high-dose methotrexate IV 4 hour day 141 , 148 , 176 , 183 , 211 , 218 , 246 , 253 , 281 , 288 ; cisplatin IV 4 hour day 190 289 . After completion study therapy , patient follow every 2 month 1 year , every 4 month 2 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm osteosarcoma extremity Highgrade ( grade III IV ) disease No lowgrade disease ( e.g. , parosteal periosteal osteosarcoma ) No secondary osteosarcoma ( i.e. , tumor occur radiotherapy field design prior tumor ) No Paget 's disease No known metastases PATIENT CHARACTERISTICS : Total bilirubin &lt; 2 time normal AST &lt; 2 time normal Alkaline phosphatase &lt; 2 time normal Creatinine ≤ 1.5 mg/dL OR creatinine clearance &gt; 60 mL/min LVEF ≥ 45 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior malignancy except retinoblastoma Patients familial retinoblastoma syndrome develop osteosarcoma unrelated radiotherapy ( e.g. , primary site extremity ) eligible PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy Patients retinoblastoma may receive radiotherapy orbit At least 28 day since prior initial amputation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>localize osteosarcoma</keyword>
</DOC>